

## RESTRICTION ELECTION FACSIMILE TRANSMISSION

DATE: 07/30/98

FROM/ATTORNEY: Christopher Bauer P-42,305

FIRM: Monsanto

PAGES, INCLUDING COVERSHEET:

3

PHONE NUMBER:

314 737-6257

TO EXAMINER: Elizabeth Kemmerer

ART UNIT: 1646

**SERIAL NUMBER:** 08/954.954

FAX/TELECOPIER NUMBER: (703) 305-3704

PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY FOR RESPONSES TO RESTRICTIONS.

<b>COMMENTS:</b>	•	

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.

08/954,954

**PATENT** 

Case 2991/1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I

IN RE APPLICATION OF:

Summers et al.

GROUP ART UNIT: 1646

SERIAL NUMBER: 08/954,954

EXAMINER: Elizabeth Kemmerer

FILED: October 21,1997

DATE: July 30, 1998

TITLE: Novel Erythropoietin Receptor Agonists

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office Fax No. (703) 305-3704 on July 30, 1998

S. Christopher Bauer Registration No. P-42,305

RESPONSE TO RESTRICTION AND ELECTION REQUIREMENTS

The Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

This responds to the Restriction and Election Requirements set forth in the Office Action dated July 14, 1998.

## <u>REMARKS</u>

Restriction has been imposed among eight groups of claimed subject matter:

- Claims 1-14, drawn to EPO receptor agonist, compositions comprising same, nucleic acid molecule encoding same, and method of administering same.
- Claims 15-22, drawn to ex vivo expansion of erythroid progenitors and methods of administration of cells.

Applicants elect, with traverse, to prosecute the subject matter of Group I as found in Claims 1-14. Applicants' reasons for traverse is that the searching of the two claimed groups does not pose an undue burden of examination on the Examiner.

2002

If the per se proteins, as claimed in group I, are novel over the prior art then the ex vivo expansion of erythroid progenitors and administering the expanded cells, as claimed in group II, would also be novel over the prior art. Therefore, examination of claims 1-22 does not pose an undue burden of on the Examiner.

If the restriction requirement is made final, applicants reserve the right to continue prosecution of non-elected Claims 15-22 (Group II) in one or more continuing applications.

Respectfully submitted,

S. Christopher Bauer

Registration No. P-42,305

Telephone: 314-737-6257

G.D. Searle & Co. Corporate Patent Department P.O. Box 5110 Chicago, Illinois 60680